Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).
GlaxoSmithKline (GSK) has announced a purchase of 485,032 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at prices ranging from 1,390.00p to 1,405.00p, will be held as treasury shares. This transaction, executed through Merrill Lynch International, is part of an agreement initiated on 4 June 2025. Following this purchase, GSK holds 225,206,623 shares in treasury, with a total of 4,090,138,849 shares in issue. The buyback program is aimed at optimizing the company’s capital structure and providing value to shareholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall score reflects strong financial stability and strategic initiatives in specialty medicines, despite technical challenges. The company’s focus on shareholder value through dividends and buybacks supports its current valuation, while recent earnings calls indicate a positive outlook for future growth.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
Average Trading Volume: 10,409,484
Technical Sentiment Signal: Hold
Current Market Cap: £56.44B
For an in-depth examination of GSK stock, go to TipRanks’ Overview page.